Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

FDA Gives Thumbs Up To Designer Babies

Monday, March 2, 2015 6:02
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Image result for genetically modified babies
The Food and Drug Administration (FDA) has finally given 23&Me (23M) their approval to market their designer baby kit to be used to determine genetic markers for Bloom Syndrome (BS), a condition associated with “short stature, sun sensitivity, and increased cancer risk.” 23M is a genetics corporation owned by Anne Wojcicki, estranged wife of Google founder Sergey Brin, and funded by Google and Google Ventures with an initial investment of $161 million. Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Health (IVDRH) at the FDA Center for Devices and Radiological Health (CDRH) explained: “The FDA believes that in many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information. [This] authorization and accompanying classification, along with FDA’s intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers. These tests have the potential to provide people with information about possible mutations in their genes that could be passed on to their children.”
Credit to Skywatch.com

http://nunezreport.blogspot.com/



Source: http://nunezreport.blogspot.com/2015/03/fda-gives-thumbs-up-to-designer-babies.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.